Home / Private raises / NewcelX Ltd.
NewcelX Ltd.
Biotechnology · Kloten, Switzerland · $5.8M sold across 2 offerings
Form D filings (2)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-11-18 | D (new) | $2.9M | $2.9M | 5 | 506(b) | Equity, Options/warrants, Security to be acquired, Common shares and warrants to purchase common shares | Nov 9 | SEC ↗ |
| 2026-08-24 | D (new) | $2.9M | $2.9M | 5 | 506(b) | Equity, Options/warrants, Security to be acquired, Common shares and warrants to purchase common shares | Jul 3 | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Issuer
| Industry | Biotechnology |
| Located | Kloten, Switzerland |
| Entity | Other |
| Incorporated | Switzerland |
| SEC CIK | 1783036 |
People named in the latest filing
| Name | Role |
|---|---|
| Ronen Twito | Executive Chairman and Chief Executive Officer |
| Michel Revel | Executive Officer, Director |
| Kfir Molakandov | Executive Officer |
| Omri Hagai | Chief Financial Officer |
| Alexander C. Zwyer | Executive Officer, Director |
| Olivier Samuel | Director |
| Eran Iohan | Director |
| Liora Oren | Director |
| Tamar Galili | Director |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
